This site is intended for Healthcare Professionals only


Key clinical developments in 2023

This module is suitable for use as part of pharmacists’ continuing professional development, a key component of the revalidation process. After reading this module in the magazine or online at, you can include it in your personal Pharmacy Magazine revalidation record.

Key facts

  • Community pharmacies in England will be able to provide clinically appropriate prescription medicines via PGDs for seven common conditions in 2024
  • The POM to P switch of tadalafil is a new treatment option for erectile dysfunction
  • Semaglutide (Wegovy) is now licensed for obesity
  • Emollient bath additives are no longer recommended in eczema (NICE update)
  • Updates in NICE UTI guidelines pave the way for pharmacist consultations as part of the Pharmacy First common conditions programme (see also first bullet point)
  • Pholcodine-containing medicines were withdrawn from the market in 2023.

Contributing author

Nicola Tyers, director, The Pharmacy Training Company and senior lecturer at Medway School of Pharmacy

Copy Link copy link button